Lead Product(s) : EB005
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : GSK
Deal Size : $224.0 million
Deal Type : Collaboration
Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million
Details : Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in a...
Product Name : EB005
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 01, 2021
Lead Product(s) : EB005
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : GSK
Deal Size : $224.0 million
Deal Type : Collaboration